P

Puma Biotechnology
D

PBYI

2.75500
USD
-0.04
(-1.43%)
Market Closed
Volume
0
EPS
0
Div Yield
-
P/E
6
Market Cap
135,236,569
OverviewSignalsIdeasNews
Related Instruments
    B
    BLUE
    -0.69000
    (-7.52%)
    8.49000 USD
    I
    INCY
    1.910
    (2.85%)
    68.910 USD
    N
    NKTR
    -0.02540
    (-2.69%)
    0.92000 USD
    S
    SGMO
    0.17500
    (7.56%)
    2.49000 USD
    X
    XLRN
    0
    (0%)
    0.000000 USD
    More
News

Title: Puma Biotechnology

Sector: Healthcare
Industry: Biotechnology
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.